Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 30,36€(+69,80%). Der Median liegt bei 30,64€(+71,36%).
| Kaufen | 5 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.» Mehr auf benzinga.com
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.» Mehr auf globenewswire.com
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, ArriVent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of common stock and shares of common stock underlying pre-funded warrants on the same terms and conditions. All of the securities are being offered by ArriVent.» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | - |
| Nettoeinkommen | −59,52 Mio | 268,80% |
| EBITDA | −61,72 Mio | 222,20% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 604,09 Mio€ |
Anzahl Aktien | 34,21 Mio |
52 Wochen-Hoch/Tief | 30,96€ - 13,17€ |
| Dividenden | Nein |
Beta | 1,27 |
KGV (PE Ratio) | −5,52 |
KGWV (PEG Ratio) | 0,10 |
KBV (PB Ratio) | 3,47 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
ArriVent BioPharma, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Identifizierung, Entwicklung und Vermarktung von Medikamenten für den ungedeckten medizinischen Bedarf von Krebspatienten befasst. Es beschäftigt sich auch mit der Entwicklung und Vermarktung von gezielten Krebstherapien für nicht-kleinzelligen Lungenkrebs (NSCLC) und andere solide Tumore. Das Unternehmen entwickelt Furmonertinib, einen epidermalen Wachstumsfaktor-Rezeptor-Mutanten-selektiven Tyrosinkinase-Inhibitor, der sich in einer klinischen Phase-3-Studie zur Behandlung von NSCLC-Patienten befindet, sowie ARR-002. Es unterhält strategische Kooperationen mit Aarvik Therapeutics Inc. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Newtown Square, Pennsylvania.
| Name | ARRIVENT BIOPH.INC. O.N. Aktie |
| CEO | Zhengbin Yao |
| Sitz | Newtown Square, USA |
| Website | |
| Börsengang | |
| Mitarbeiter | 52 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | AVBP |
Assets entdecken
Shareholder von ARRIVENT BIOPH.INC. O.N. Aktie investieren auch in folgende Assets
